# Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

> **NCT01465815** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **OHSU Knight Cancer Institute**

## Conditions studied

- Recurrent Skin Cancer
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Squamous Cell Carcinoma of the Skin
- Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** linsitinib
- **DRUG:** placebo
- **RADIATION:** radiation therapy
- **PROCEDURE:** therapeutic conventional surgery
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01465815
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-12
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and OSI-906 in other oncology studies was determined to be unfavorable.
- **Last updated:** 2014-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01465815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01465815, "Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01465815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*